KDR and neoplasm: For example a murine study using Colon-26 adenocarcinoma demonstrated that simultaneous treatment with anti-PD-1 and anti-VEGFR2 monoclonal antibodies resulted in a synergistically increased inhibition of tumor growth compared with either therapy alone without excess toxicity (77).